|Home | About | Journals | Submit | Contact Us | Français|
SAMHD1 is a viral restriction factor expressed in dendritic cells and other cells, inhibiting infection by cell-free human immunodeficiency virus type 1 (HIV-1) particles. SAMHD1 depletes the intracellular pool of deoxynucleoside triphosphates, thus impairing HIV-1 reverse transcription and productive infection in noncycling cells. The Vpx protein from HIV-2 or simian immunodeficiency virus (SIVsm/SIVmac) antagonizes the effect of SAMHD1 by triggering its degradation. A large part of HIV-1 spread occurs through direct contacts between infected cells and bystander target cells. Here, we asked whether SAMHD1 impairs direct HIV-1 transmission from infected T lymphocytes to monocyte-derived dendritic cells (MDDCs). HIV-1-infected lymphocytes were cocultivated with MDDCs that have been pretreated or not with Vpx or with small interfering RNA against SAMHD1. We show that in the cocultures, SAMHD1 significantly inhibits productive cell-to-cell transmission to target MDDCs and prevents the type I interferon response and expression of the interferon-stimulated gene MxA. Therefore, SAMHD1, by controlling the sensitivity of MDDCs to HIV-1 infection during intercellular contacts, impacts their ability to sense the virus and to trigger an innate immune response.
Dendritic cells (DCs) are professional antigen-presenting cells linking innate and adaptive immune responses. DCs generally recognize pathogens in the periphery and then mature and migrate to lymphoid tissues to elicit a response. This process involves expression of costimulatory molecules and production of type I interferons (IFNs) and cytokines. IFN secretion induces numerous interferon-stimulated genes (ISGs) that help control viral replication and activates immunity (1).
Viruses use multiple mechanisms to avoid innate sensing, cytokine production, antiviral activity of ISGs, and restriction factors (1–3). For HIV-1, the proteins Vif and Vpu counteract the effects of the restriction factors APOBEC and tetherin. APOBEC proteins induce G-to-A hypermutations in the nascent viral DNA during reverse transcription, while tetherin blocks viral release (2). Other primate lentiviruses (human immunodeficiency virus type 2 [HIV-2] and simian immunodeficiency virus [SIV]) possess an additional protein, Vpx, whose function has recently been deciphered (4–8). Vpx facilitates replication of HIV-2 and some SIV in myeloid cells but is dispensable in cycling lymphocytes (4). Vpx triggers the destruction of an early-acting restriction factor and promotes synthesis of viral DNA in nondividing cells (6). This restriction factor is active against not only HIV-2 and SIV but also retroviruses like HIV-1 that lack Vpx.
Monocyte-derived DCs (MDDCs) express receptors allowing HIV-1 capture and entry and efficiently transmit the virus to activated CD4+ T cells but are poorly sensitive to productive HIV-1 infection. However, intracellular delivery of Vpx to MDDCs, through treatment with nonreplicative SIV particles carrying Vpx, dramatically enhances HIV-1 infection (6, 9). Vpx acts by inducing the nuclear degradation of SAMHD1, a cellular protein found in various cell types, including myeloid cells (5, 7, 10, 11) and CD4+ T lymphocytes (12–15). SAMHD1 is a deoxynucleoside triphosphohydrolase that cleaves deoxynucleotide triphosphates (dNTPs) (16, 17). SAMHD1 is primarily localized in the nucleus and depletes the pool of intracellular nucleotides in noncycling cells (11, 18). In myeloid cells, in the presence of SAMHD1, the low levels of dNTPs are not sufficient to allow potent and rapid HIV-1 replication, but minimal viral growth can be achieved (11, 18). SAMHD1 also restricts HIV-1 reverse transcription in quiescent CD4+ T cells (12–15). Before being identified as an anti-HIV-1 restriction factor, SAMHD1 was reported to be deficient in individuals with Aircaidi-Goutières syndrome (AGS), an autoimmune disease mimicking signs of congenital viral infection with spontaneous production of type I IFNs (19). Monocytes from AGS patients with mutated SAMHD1 are sensitive to HIV-1 (20).
The low sensitivity of MDDCs to productive HIV-1 infection has important consequences on virus sensing and type I IFN production by these cells. In the presence of Vpx, HIV-1-infected MDDCs readily mature and release type I IFN, revealing a cryptic mechanism of HIV-1 recognition (20–22). Similarly, an HIV-1 strain modified to package SIV Vpx efficiently replicates in MDDCs and induces a potent type I IFN response (23). These observations raised the hypothesis that SAMHD1, in addition to impairing HIV-1 replication, may also influence the triggering of an immune response in myeloid MDDCs.
Most, if not all, of the studies regarding the sensitivity of MDDCs to HIV-1 and the impact of SAMHD1 have been performed using cell-free virions (7, 21). However, HIV-1 replication occurs efficiently through cell-to-cell contacts (24–26). In lymphocytes, these contacts lead to the formation of virological synapses, which are cohesive supramolecular structures allowing rapid transfer of budding viruses to new target cells. The passage of HIV-1 occurs between lymphocytes but also between other cell types. The virus is efficiently transmitted from infected macrophages to T cells, across transient adhesive contacts (27). MDDCs capture cell-free virions and transmit the virus to CD4+ T cells, a phenomenon improved by DC maturation (28, 29). HIV-1 spreads from virus-containing MDDCs that are not necessarily productively infected to T cells via a so-called infectious synapse (30–32). Much less is known about the ability of infected lymphocytes to propagate the infection to MDDCs. HIV-1-infected lymphocytes form abnormal immunological synapses with antigen-presenting cells (33–35), likely altering the function and fate of lymphocytes. Contacts between infected T cells and MDDCs induce effective viral capture (28), but subsequent events leading to productive infection of MDDCs have not been thoroughly characterized.
From the standpoint of innate immunity, HIV-1-infected cells are more potent inducers of type I IFN than virions. For example, plasmacytoid dendritic cells (pDCs) rapidly detect HIV-1-infected cells, mainly through Toll-like receptor 7 (TLR7), leading to type I IFN secretion (36). How MDDCs react and produce IFN when they encounter infected lymphocytes is less well defined.
Here, we asked whether HIV-1 can be transmitted from infected lymphocytes to cocultivated MDDCs and examined the effect of SAMHD1 on viral transmission and triggering of the type I IFN response.
Buffy coats from human healthy donors were obtained from the Etablissment Français du Sang. Monocytes were isolated using a CD14+ selection kit (Miltenyi Biotech). MDDCs were generated by culturing monocytes with 50 ng ml−1 interleukin-4 (IL-4) and 10 ng ml−1 granulocyte-macrophage colony-stimulating factor for 5 days. Purified CD4+ T cells were stimulated with phytohemagglutinin (1 μg ml−1) for 24 h and cultured with IL-2 (50 U ml−1). MT4 cells and cells of the HL116 cell line were grown as described previously (36).
NL4-3 and NLAD8 HIV-1 strains and the primary isolate 132W (37) were produced in MT4 cells. Vesicular stomatitis virus G glycoprotein (VSV-G)-pseudotyped viruses and green fluorescent protein (GFP)-expressing lentiviral particles (LV-GFPs) were generated as described previously (38). SIV type 3 (SIV-3)-positive wild-type and the ΔVpx plasmids (a kind gift from Monsef Benkirane) were used to produce virion-like particles (VLPs) as described previously (7, 39). Influenza virus A (FLUAV; A/PR/8/34) was from Charles River Laboratories and used at 10 hemagglutination units (HAU) ml−1, unless otherwise specified. The reverse transcriptase inhibitor nevirapine (NVP) (used at a final concentration of 6.25 μg ml−1) and the integrase inhibitor raltegravir (used at a final concentration of 1 μM ml−1) were from the NIH AIDS Reagents Program.
A pool of small interfering RNA (siRNA) against SAMHD1 (L-013950-01; Dharmacon) and, as a negative control, siRNA against dynamin-2 (control siRNA [siCTR]; L-004007-00; Dharmacon) were used. MDDCs (5 × 105) were transfected with 100 nM siRNA using the HiPerFect reagent (Qiagen) in 12-well plates, with two rounds of transfection as described previously (7). SAMHD1 silencing was assessed by flow cytometry and immunoblotting 24 h later. At that time, MDDCs were transduced with LV-GFPs (100 ng ml−1). Two days after transduction, the level of GFP-expressing cells was checked by flow cytometry.
MDDCs were seeded in flat-bottomed 96-well plates at 1 × 106 MDDCs per well. MT4 or primary CD4+ T cells were infected with HIV(VSV) 2 days before the start of the coculture. Donor T cells were stained with 5-chloromethylfluorescein diacetate (CMFDA; Invitrogen) as described previously (36). MT4 and CD4+ T cells were then cocultivated with MDDCs at a 1:2 ratio (T cells/MDDCs). Noninfected T cells were used as negative controls. Cocultures were performed for 48, 72, or 96 h. Cell-free NL4-3, NLAD8, and 132W virions and HIV(VSV) pseudotypes were used at 100 ng ml−1 of p24. When stated, VLPs were added to MDDCs 2 h before HIV-1 infection and maintained during the experiment. Shaking and transwell experiments were performed as described previously (26).
Lysates from MDDCs were analyzed for expression of SAMHD1 and β-actin as described previously (7). The polyclonal anti-SAMHD1 antibody (Abcam) and the monoclonal anti-β-actin (clone AC-15; Sigma) were used at 1/5,000.
To stain SAMHD1, a nuclear protein, MDDCs were fixed with phosphonoformic acid (4%) for 10 min, followed by permeabilization with phosphate-buffered saline–azide and Triton X-100 0.5% for 20 min. Cells were stained either with the mouse monoclonal IgG1 anti-SAMHD1 antibody (clone I19-18) coupled with Alexa 488 or with a rabbit polyclonal anti-SAMHD1 (12586-1-AP; Proteintech) for 20 min at room temperature. I19-18 antibody was generated by the Institut Pasteur antibody production core facility, using a recombinant SAMHD1–glutathione S-transferase protein as an antigen. It was selected for its ability to recognize SAMHD1 in Western blot and flow cytometry assays. Double Gag and MxA stainings were performed with the Gag KC57 (Beckman and Coulter) and MxA (clone MN143, provided by Otto Haller) antibodies as described previously (36). The anti-nucleoprotein (anti-NP) FLUAV monoclonal antibody (ATCC HB-65) was used to monitor infection of MDDCs by flow cytometry. Samples were analyzed with a Canto II fluorescence-activated cell sorter from Becton, Dickinson.
Type I IFN secretion was quantified using a reporter cell line, HL116, that carries the luciferase gene under the control of the IFN-inducible 6-16 promoter, as described previously (36). IFN levels are expressed as the equivalent of the alpha 2a IFN (IFN-α2a) concentration (in picomolar).
We asked whether preincubation of MDDCs with VLPs enhances their sensitivity to infection via HIV-1-infected cells, as is the case of cell-free HIV-1 infection. Exposure of MDDCs to VLPs strongly reduced the levels of SAMHD1, as observed by flow cytometry and Western blotting (Fig. 1A). Depending on the donors, 80 to 100% of the DC population displayed low to undetectable levels of SAMHD1 (Fig. 1 and not shown). As expected, the VLPs dramatically increased the efficiency of MDDC transduction with a GFP-encoding lentiviral vector (LV-GFP) (mean, 16-fold increase of GFP-positive [Gag+] cells with five independent donors) (Fig. 1B).
We then evaluated the effect of Vpx on MDDC infection by cell-free HIV-1. MDDCs were incubated for 2 h with or without VLPs before exposure to HIV(VSV), a VSV-pseudotyped HIV-1. The extent of infection was measured by flow cytometry, at 48 and 72 h postinfection, by performing double HIV-1 Gag and SAMHD1 staining (Fig. 1C). The results of one representative experiment are shown Fig. 1C, and the mean values obtained with eight independent donors are shown in Fig. 1D. Without VLPs, the efficiency of infection was low, with 5 and 10% of cells being Gag+ at 48 and 72 h, respectively. The Gag signal corresponded to newly synthesized viral proteins, since it was no longer detected when MDDCs were treated with the reverse transcriptase inhibitor NVP (Fig. 1D). As previously reported (7), VLPs strongly increased the number of infected cells (Fig. 1C and andD).D). Interestingly, the Gag-expressing cells were mostly found within the SAMHD1-low population (Fig. 1C), confirming that SAMHD1 prevents efficient HIV-1 infection in MDDCs.
We next asked whether HIV-1 cell-to-cell transmission to MDDCs could overcome the antiviral effect of SAMHD1. We set up a coculture system, in which HIV-1-infected T cells are mixed with target MDDCs (Fig. 2A). We used a T cell line (MT4) or autologous primary CD4+ T cells as donors. The T cells were infected 2 days before the coculture, in order to get a significant proportion of HIV-1-producing cells. HIV-infected T cells were stained with the CMFDA tracker before coculture, to distinguish donor and target cells. MDDCs were incubated or not with VLPs 2 h before addition of donor cells. Infection of MDDCs was measured at 48 and 72 h postcoculture by double Gag and SAMHD1 staining (Fig. 2B and andC).C). In this coculture system, in the absence of Vpx (−VLP), MDDCs were poorly sensitive to infection. One experiment and the mean values of independent experiments with 9 donors are shown in Fig. 2B. Even though MT4 cells were highly infected at the beginning of the coculture (40 to 80% of Gag+ cells; not shown), only 8 and 12% of MDDCs became infected at 48 and 72 h, respectively (Fig. 2B). The Gag signal in MDDCs was significantly reduced in the presence of NVP, indicating that it mostly corresponded to productive infection and not to capture of incoming viral material (Fig. 2B and andCC).
Interestingly, addition of VLPs to MDDCs decreased SAMHD1 levels and significantly enhanced the appearance of Gag-expressing MDDCs (Fig. 2B). Similar results were obtained with HIV-1-infected primary autologous CD4+ T cells (with 10 to 20% of Gag+ cells; not shown) used as donors (Fig. 2C).
A large part of HIV-1-infected MT4 cells died during the coculture, as assessed by calculating the percentage of donor cells in the coculture at 72 h (not shown). This death was likely due to a viral cytopathic effect, since noninfected MT4 cells remained detectable. Primary infected CD4+ T cells, which are less prone to HIV-1-induced cytopathic effects, at least during the 3 days of the experiment, were still present in the coculture after 72 h (not shown).
Noteworthy, VLPs devoid of Vpx (VLPΔVpx) did not downregulate SAMHD1 (not shown), nor did they enhance HIV-1 infection (Fig. 2D), confirming that Vpx is required to mediate these effects.
Numerous clusters of infected lymphocytes and MDDCs were observed in the coculture (not shown). Moreover, the separation of donor T cells and target MDDCs in transwell chambers or application of a gentle and continuous shaking to the cocultures to avoid long contacts between cells (26) significantly decreased the percentage of infected MDDCs (Fig. 2E), strongly suggesting that most of the virus was transmitted through cell-to-cell contacts.
Altogether, these results show that HIV-1 cell-to-cell transmission to MDDCs is less efficient in the absence of Vpx, suggesting that contacts with infected cells do not overcome HIV-1 restriction in MDDCs.
In contrast to pDCs (21, 36, 40), MDDCs do not produce detectable levels of type I IFN when exposed to cell-free HIV-1. However, the addition of Vpx in MDDCs, by allowing HIV-1 infection, promotes IFN release (21). We previously reported that HIV-infected T cells are much more potent inducers of type I IFN than free virions in pDCs (36). We asked whether SAMHD1 might prevent recognition of cell-free HIV-1 and HIV-1-infected T cells by MDDCs.
We first examined the impact of VLPs on the sensing of virions. MDDCs that were initially analyzed for their sensitivity to HIV(VSV) (Fig. 1D) were further stained for MxA, an interferon-stimulated gene (36, 41). Flow cytometry indicated that MxA was strongly induced by virions only in the presence of VLPs (Fig. 3A and andB).B). Expression of MxA was induced in both infected and bystander MDDCs (Fig. 3A), demonstrating a paracrine effect. Furthermore, MxA induction correlated with a release of type I IFN in supernatants (Fig. 3B, right). NVP not only blocked HIV-1 infection but also prevented MxA expression and IFN release (Fig. 3B). VLPs also increased infection of the X4 strain NL4-3, the R5 strain NLAD8, and the primary dual-tropic 132W isolate (Fig. 3C), indicating that the enhancing effect of Vpx is not limited to VSV-pseudotyped viruses. These non-VSV-pseudotyped HIV-1 isolates similarly triggered an IFN response, but only in the presence of Vpx (Fig. 3C). Of note, cells from two out of eight independent donors did not release detectable IFN in response to cell-free HIV-1, even though VLPs enhanced infection. FLUAV, a well-characterized IFN inducer, was used as a positive control. As expected (42), FLUAV productively infected MDDCs, as assessed by flow cytometry after staining with an anti-NP antibody (not shown). FLUAV induced similar levels of MxA and type I IFN, irrespective of Vpx (Fig. 3D).
We then determined how VLPs affected sensing of HIV-1-infected T cells by MDDCs. Without VLPs, HIV-infected MT4 cells did not trigger a potent immune response in MDDCs (Fig. 4A and andB).B). Addition of VLPs induced MxA expression in MDDCs and IFN release in the cocultures (Fig. 4A and andB).B). HIV-1-infected autologous CD4+ T cells also induced MxA and IFN in the presence of VLPs (Fig. 4A and andC);C); however, induction was at levels lower than those for MT4 cells. For example, MxA was significantly upregulated at the 48-h time point with MT4 cells and only at 72 h with primary lymphocytes. NVP inhibited infection of MDDCs (Fig. 2) and sensing of infected T cells (Fig. 4). The integrase inhibitor raltegravir also inhibited productive infection of MDDCs cultivated with infected MT4 cells and impaired MxA expression in MDDCs (Fig. 4D).
Therefore, MDDCs do not spontaneously trigger an IFN response when they encounter HIV-1-infected T cells. The addition of Vpx overcomes restriction to HIV-1 infection and promotes sensing of HIV-1-infected T cells.
To further study the role of SAMHD1 in HIV-1 infection and sensing in MDDCs, we silenced this protein with siRNA. As previously reported, transfection of siRNA against SAMHD1 (and not that of a control siRNA, siCTR) (7) induced SAMHD1 silencing, with 40 to 60% decreases in the levels of the protein, depending on the donors, being observed by flow cytometry and Western blotting (Fig. 5A). Thus, the silencing procedure decreases SAMHD1 levels, but the degradation that it induces is less potent than the degradation induced by Vpx (compare Fig. 1A and and5A).5A). As expected, in SAMHD1-silenced cells, there was a strong increase of transduction with LV-GFPs (Fig. 5B). Infection of MDDCs with free HIV(VSV) was also significantly augmented (Fig. 5C and andD).D). The MxA protein was induced upon HIV-1 infection in SAMHD1-silenced cells (Fig. 5C and andD).D). MxA induction was significant but less marked than that in VLP-exposed MDDCs (Fig. 3). We hypothesize that the residual levels of SAMHD1 may partly protect MDDCs against HIV-1 infection and sensing.
SAMHD1 silencing also facilitated infection of MDDCs cocultivated with HIV-1-infected T cells (Fig. 6). A significant 2-fold increase in the proportion of Gag+ MDDCs was detected. Again, this augmentation was less marked than that in VLP-exposed MDDCs but was associated with viral sensing and expression of the MxA protein in MDDCs (Fig. 6C).
We only occasionally detected type I IFN release in the supernatants of SAMHD1-silenced MDDCs exposed to cell-free HIV(VSV) or cocultivated with HIV-infected lymphocytes (not shown). This might be due to the relatively low MDDC concentration in cultures after siRNA transfection, a procedure that can be harmful for the cells.
MT4 cells are better HIV-1 transmitters and trigger a stronger innate response than primary CD4+ T cells in MDDCs (Fig. 2 and and4).4). We asked whether there is a correlation between the levels of Gag and the induction of MxA in MDDCs. Plotting of these two parameters, irrespective of any VLP treatment or any SAMHD1 silencing, demonstrated a correlation, with a threshold of innate detection at about 20% of Gag-positive MDDCs (not shown). This correlation was visible with both HIV-1 cell-free particles and infected cells (not shown).
Therefore, siRNA transfection allows a partial but significant reduction of SAMHD1 levels in MDDCs. SAMHD1-silenced cells are more sensitive to infection by virions or by coculture with infected lymphocytes. Moreover, in silenced cells, infection triggers innate sensing of the virus, as assessed by MxA expression. This phenomenon is more pronounced with HIV-1-infected T cells than with free virions. High levels of productive infection in MDDCs are required to induce sensing. Altogether, our results highlight a role for SAMHD1 in controlling HIV-1 immune recognition by MDDCs.
Myeloid DCs are poorly permissive to infection by cell-free HIV-1. In these noncycling cells, viral reverse transcription occurs slowly and almost covertly (43), because of a limited availability of intracellular dNTPs (11, 18). The recently identified deoxynucleoside triphosphohydrolase SAMHD1 cleaves dNTPs and thus acts as an antiviral protein in MDDCs and other myeloid cells (11, 16). We show here that MDDCs are to a large extent resistant to infection when they encounter HIV-1-infected cells. Mixing infected lymphocytes with MDDCs led to a modest infection, with less than 10% of MDDCs expressing Gag 2 or 3 days after the beginning of the coculture. This restriction of infection is in large part mediated by SAMHD1. SAMHD1 levels are not modified in MDDCs cocultivated with infected lymphocytes. Moreover, addition of SIV particles carrying the lentiviral protein Vpx, which degrades SAMHD1, or silencing of SAMHD1 with siRNAs significantly enhanced productive infection of MDDCs. Our results strongly suggest that contacts with HIV-1-infected lymphocytes do not affect SAMHD1 activity in MDDCs and thus do not lead to an increase of the intracellular dNTP pool.
Direct intercellular transmission of HIV-1 is far more efficient than infection with free virions (24, 26). The high multiplicity of infection generated during the formation of virological synapses may allow escape from antiviral immune responses and therapeutics (37, 44). The antiviral activity of some restriction factors is saturable. For instance, Trim5a, which targets incoming lentiviral capsids, does not prevent cell-to-cell transmission (45). In contrast, tetherin, which sequesters budding virions at the cell surface, inhibits this mode of viral spread (46, 47). Given that SAMHD1 degrades cellular dNTPs, it is not unexpected to observe that the enzyme inhibits HIV-1 cell-to-cell transmission. Moreover, SAMHD1 binds RNA, and this binding inhibits its enzymatic activity (48, 49). Recent enzymatic analysis also showed that SAMHD1 does not hydrolyze ribonucleoside triphosphates (rNTPs) or single-stranded DNA, double-stranded DNA, or RNA (16). These assays were carried out with a recombinant protein in vitro and do not formally rule out the possibility that the enzyme may target additional viral or cellular nucleic acids within the cell. Furthermore, coculture of MDDCs with infected CD4+ T cells could have affected the expression or function of SAMHD1, but our results demonstrate that this is not the case. It might have also been conceivable that during coculture and viral cell-to-cell transmission, dNTPs carried over from T cells to MDDCs might have overcome SAMHD1 restriction. Again, this is apparently not the case. Altogether, our results show that SAMHD1, due to its original mode of action, is not saturable and remains operative during HIV-1 intercellular spread.
Silencing of SAMHD1 significantly relieved the block to HIV-1 intercellular transmission, although less efficiently than the addition of Vpx to MDDCs. This may be due to the incomplete silencing achieved by siRNA, which led to residual levels of SAMHD1. It is also possible that Vpx exerts additional, SAMHD1-independent effects to facilitate infection (50). Vpx has been reported to bind and partially counteract another cellular protein, APOBEC3A, which may inhibit HIV-1 infection in myeloid cells (51, 52). It will be of interest to assess whether SAMHD1 exerts its antiviral activity in coordination with other enzymes regulating the dNTP pool or the metabolism of nucleic acids.
During chronic HIV infection, circulating myeloid DC numbers are reduced (53). Moreover, the frequency of infected MDDCs in HIV-1-positive individuals is low, probably 10- to 100-fold lower than that of infected CD4 T cells (29). The reasons explaining this moderate susceptibility are multiple and include low levels of HIV receptors, a rapid and extensive degradation of internalized HIV, and as demonstrated here, the presence of the restriction factor SAMHD1, which may prevent HIV-1 cell-to-cell transmission in vivo.
Why does HIV-1 not possess a protein with anti-SAMHD1 activity, in contrast to HIV-2 and SIV? HIV-1 encodes a reverse transcriptase with a low Km (54) that binds to dNTPs with a particularly high affinity. This property contributes to the low levels of reverse transcription in noncycling myeloid cells, in which dNTPs are scarce (4, 11, 18). The HIV-2 reverse transcriptase probably has a lower affinity for dNTPs (50), which may be detrimental for this virus in noncycling cells. It has been reported that DCs are less susceptible to HIV-2 than to HIV-1, when the infection is performed with cell-free virions (55). It will be worth examining whether HIV-2 more efficiently infects MDDCs by cell-to-cell transmission and, if so, to evaluate the impact of Vpx on this phenomenon.
The lack of Vpx in HIV-1 has also been proposed to allow avoiding an immune response in MDDCs (21). Indeed, MDDCsinfected with HIV-1 produced type I IFN and upregulated CD86 only in the presence of Vpx (21, 23). Our results extend these observations. We show here that in the absence of Vpx, neither free virions nor HIV-1-infected cells trigger detectable IFN release by MDDCs, although very modest effects can rarely be observed in some donors. However, addition of VLPs promoted sensing of HIV-1, assessed by measuring type I IFN production and MxA expression. MxA is widely used as a surrogate marker of IFN production (41). MxA is induced by type I IFN and the closely related type III IFN but not by type II IFN. It will be worth determining whether type III IFN and other cytokines are also induced upon sensing of HIV-1 by MDDCs. Interestingly, HIV-1-infected T cells are more potent inducers of IFN than free virions (compare Fig. 3 and and4),4), in line with our previous results obtained in other hematopoietic cell types (peripheral blood mononuclear cells and pDCs) (36). Future studies will help determine which viral or cellular components allow potent sensing of infected cells.
The reverse transcriptase inhibitor NVP prevented MDDC responsiveness, indicating that incoming viral RNA is not sufficient to induce IFN production. The integrase inhibitor raltegravir also inhibited sensing of HIV-infected cells. This result suggested that the response was triggered postintegration, consistent with the findings of Manel et al. (21) and Sunseri et al. (23), obtained with cell-free viral particles. This result also suggests that incomplete reverse transcripts, which are known to trigger an inflammatory response in CD4+ T cells (56), are poorly sensed in MDDCs. It will be worthwhile to test various viral mutants to further characterize which steps of the viral life cycle, after reverse transcription and integration, mediate the sensing of infection in MDDCs. In particular, when the infection is performed with cell-free HIV-1, sensing involves binding of cyclophilin A to newly synthesized Gag proteins (21). It is tempting to speculate that additional pathways of sensing may be triggered upon cell-to-cell contacts.
Silencing of SAMHD1 promoted HIV-1 recognition, demonstrating that this restriction factor negatively regulates virus-induced immune responses in MDDCs. In line with our data, monocytes from individuals with Aicardi-Goutieres syndrome are highly susceptible to HIV-1 and produce proinflammatory cytokines upon infection (20). Therefore, the restriction of HIV-1 infection by SAMHD1 directly impacts the triggering of an innate immune response in myeloid MDDCs. These cells have a central role in linking innate and adaptive responses. The type of innate stimuli impacts the outcome of the adaptive response, including polarization of CD4+ T cells, antibody shaping, and establishment of memory (57, 58). Furthermore, HIV-1, by avoiding efficient productive infection of MDDCs through preservation of SAMHD1, may also control the array of presented or cross-presented viral antigens, resulting in qualitatively or quantitatively different CD8+ and CD4+ responses (57, 59).
It is noticeable that there were some variations in the type I IFN/MxA responses between donors, even though the levels of virus infection showed less variation. We observed that there is a significant correlation between the levels of Gag expression and the percentage of MxA-positive cells (data not shown), and this may explain why some donors elicited clear responses to infection, whereas others did not. It is also likely that the extent of the innate response may vary between individuals. It will be of interest to analyze serial samples from the same donors, to determine if they behave consistently.
In contrast to myeloid DCs, pDCs efficiently and rapidly detect HIV-1, mainly through TLR7, leading to type I IFN secretion independently of productive infection (36, 60). It will be important to study whether pDCs, which are noncycling cells, express SAMHD1 and, if so, what are the possible effects on IFN production. Various cell types with different mechanisms are thus involved in the recognition of HIV-1 virions and infected cells. Overall, our results show that in myeloid DCs, SAMHD1 controls not only HIV-1 replication but also the immune response of the host.
We thank members of the Virus and Immunity Unit for discussions and Monsef Benkirane and Diana Ayinde for critical readings of the manuscript.
Work in our lab is supported by grants from the Agence Nationale de Recherche sur le SIDA (ANRS), SIDACTION, the AREVA Foundation, the Vaccine Research Institute, the Labex IBEID program, the FP7 program HIT Hidden HIV (Health-F3-2012-305762), and the Institut Pasteur. I.P. is supported by the Marie Curie Intra-European Fellowship for Career Development (FP-7-PEOPLE-2011-IEF).
I.P., N.C., and F.P. performed research and analyzed data. I.P., N.C., and O.S. designed the research and wrote the paper. O.S. supervised the study.
We declare no competing financial interest.
Published ahead of print 26 December 2012